{"id":2269,"date":"2022-07-26T12:20:36","date_gmt":"2022-07-26T16:20:36","guid":{"rendered":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/?page_id=2269"},"modified":"2026-02-19T22:04:49","modified_gmt":"2026-02-20T03:04:49","slug":"publications","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

Google Scholar<\/a>
\nNCBI Bibliography<\/a><\/p>\n

\n
43) Pomeroy AE, Sworder BJ, Plana D, Cao Y, Alizadeh AA, Palmer AC<\/strong> (2026)
\nA Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma<\/a>
\nBlood Cancer Discovery<\/em><\/strong> 7:p41
\nNews in\u00a0Blood Cancer Discovery<\/em><\/a><\/div>\n
42) Pantazis JC, Palmer AC<\/strong> (2025)
\nCross-resistance of Belinostat and Romidepsin in Non\u2013T Follicular Helper Peripheral T-cell Lymphoma Models Suggests Subtype-Specific Implications for Belinostat-CHOP<\/a>
\nMolecular Cancer Therapeutics<\/em><\/strong> 5:p254\n<\/div>\n
41) Pomeroy AE, Palmer AC<\/strong> (2025)
\nA model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma<\/a>
\nBlood Cancer Discovery<\/em><\/strong> 5:p254
\nNews in\u00a0Blood Cancer Discovery<\/em><\/a><\/div>\n
40) Patterson SC, Pomeroy AE, Palmer AC<\/strong> (2024)
\nUltrasensitive response explains the benefit of combination chemotherapy despite drug antagonism<\/a>
\nMolecular Cancer Therapeutics<\/em><\/strong> 23:p995<\/div>\n
39) Zhou I, Plana D, Palmer AC<\/strong> (2024)
\nTumor-specific activity of precision medicines in the NCI-MATCH trial<\/a>
\nClinical Cancer Research<\/em><\/strong> 30:786-792<\/div>\n
38) Mason-Osann E, Pomeroy AE, Palmer AC\u2021<\/strong>, Mettetal J\u2021<\/strong> (2024) (\u2021<\/strong> co-corresponding)
\nSynergistic drug combinations promote the development of resistance in Acute Myeloid Leukemia<\/a>
\nBlood Cancer Discovery<\/em><\/strong> 5:p95<\/div>\n
37) Chen JK, Merrick KA, Kong YW, Izrael-Tomasevic A, Eng G, Handly ED, Patterson JC, Cannell IG, Suarez-Lopez L, Hosios AM, Dinh A, Kirkpatrick DS, Yu K, Rose CM, Hernandez JM, Hwangbo H, Palmer AC<\/strong>, Vander Heiden MG, Yilmaz \u00d6H, Yaffe MB (2024)
\nAn RNA damage response network mediates the lethality of 5-FU in colorectal cancer<\/a>
\nCell Reports Medicine<\/strong><\/em> 5:101778<\/div>\n
36) Palmer AC<\/strong>, Kurtz DM, Alizadeh AA (2023)
\nCell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin<\/a>
\nThe New England Journal of Medicine<\/em><\/strong> 389:p764<\/div>\n
35) Hwangbo H, Patterson SC, Dai A, Plana D, Palmer AC<\/strong> (2023)
\nAdditivity predicts the efficacy of most approved combination therapies for advanced cancer<\/a>
\nNature Cancer<\/em><\/strong> 7:p247
\nNews in Cancer Discovery<\/em><\/a><\/div>\n
34) Schmidt EV, Sun LZ, Palmer AC<\/strong>, Chen C (2023)
\nRationales for Combining Therapies to Treat Cancer<\/a>
\nAnnual Review of Cancer Biology<\/em><\/strong> 7:p247<\/div>\n
\n
33) Hanh CK, Palmer AC<\/strong>, Weinstock DM (2023)
\nGenetically informed therapy for lymphoma<\/a>
\nCancer Cell<\/em><\/strong> 41:p1696<\/div>\n
32) Pomeroy A, Schmidt E, Sorger PK, Palmer AC<\/strong> (2022)
\nDrug independence and the curability of cancer by combination chemotherapy<\/a>
\nTrends in Cancer<\/em><\/strong> 8:p915<\/div>\n
31) Plana D, Fell G, Alexander BM, Palmer AC \u2021<\/strong>, Sorger PK \u2021 (2022) (\u2021<\/strong> co-corresponding)
\nCancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects<\/a>
\nNature Communications<\/em><\/strong> 13:p876<\/div>\n
30) Plana D*, Palmer AC*\u2021<\/strong>, Sorger PK\u2021 (2022) (*co-first, \u2021<\/strong> co-corresponding)
\nIndependent Drug Action in Combination Therapy: Implications for Precision Oncology<\/a>
\nCancer Discovery<\/em><\/strong> 12:p606<\/div>\n
29) Palmer AC<\/strong>, Izar B, Hwangbo H, Sorger PK (2022)
\nPredictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors<\/a>
\nClinical Cancer Research<\/em><\/strong> 28:p368
\nNews in ASCO Post, AACR, AAAS EurekAlert, STAT News, MedicalXpress, In the Pipeline<\/em><\/div>\n
28) Hemez C, Clarelli F, Palmer AC<\/strong>, Bleis C, Abel S, Chindelevitch L, Cohen T, Abel zur Wiesch P (2022)
\nMechanisms of antibiotic action shape the fitness landscapes of resistance mutations<\/a>
\nComputational and Structural Biotechnology Journal<\/em><\/strong> 20:p4688<\/div>\n
27) Palmer AC<\/strong>*, Plana D*, Sorger PK (2020) (*equal)
\nComparing the efficacy of cancer therapies between subgroups in basket trials.<\/a>
\nCell Systems<\/em><\/strong> 11:p449<\/div>\n
26) Palmer AC<\/strong>*, Plana D*, Gao H*, Korn JM, Yang G, Green J, Zhang X, Velazquez R, McLaughlin ME, Ruddy DA, Kowal C, Goldovitz J, Bullock C, Rivera S, Rakiec D, Elliott G, Fordjour P, Meyer R, Loo A, Kurth E, Engelman JA, Bitter H, Sellers WR, Williams JA, Sorger PK (2020) (*equal)
\nA proof of concept for biomarker-guided targeted therapy for ovarian cancer based on patient-derived tumor xenografts.<\/a>
\nCancer Research<\/em><\/strong> 80:p4278<\/div>\n
25) Clarelli F, Palmer AC<\/strong>, Singh B, Storflor M, Lauksund S, Cohen T, Abel S, Abel zur Wiesch P (2020)
\nDrug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones<\/a>.
\nPLOS Computational Biology<\/em><\/strong> 16:e1008106<\/div>\n
24) He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC<\/strong>, Zheng G, Weinstock DM, Zhou D (2020)
\nDT2216\u2014a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.<\/a>
\nJournal of Hematology & Oncology<\/em><\/strong> 13:p95<\/div>\n
23) Chopra SS, Jenney A, Palmer AC<\/strong>, Niepel M, Chung M, Mills C, Sivakumaren SC, Liu Q, Chen JY, Yapp C, Asara JM, Gray NS, Sorger PK (2020)
\nTorin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.<\/a>
\nCell Systems<\/em><\/strong> 10:p66<\/div>\n
22) Palmer AC<\/strong>*, Chidley C*, Sorger PK (2019) (*equal)
\nA curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.<\/a>
\neLife<\/em><\/strong> 8:e50036<\/div>\n
21) Wang H, Sheehan RP, Palmer AC<\/strong>, Everley RA, Boswell SA, Ron-Harel N, Holton KM, Jacobson CA, Erickson AR, Maliszewski L, Haigis MC, Sorger PK. (2019)
\nAdaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.<\/a>
\nCell Systems<\/em><\/strong> 8:p412<\/div>\n
20) Nan N*, Crooks M*, Palmer AC<\/strong>, Dodd IB, Shearwin KE. (2019)
\nRNA polymerase pausing at a protein roadblock can enhance transcriptional interference by promoter occlusion.<\/a>
\nFEBS Letters<\/em><\/strong> 593:p903<\/div>\n
19) Koch R, Christie AL, Crombie JL, Palmer AC<\/strong>, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller A, Cidado J, Letai A, Weinstock DM (2019)
\nBiomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.<\/a>
\nBlood<\/em><\/strong> 133:p566
\nNews in Blood<\/em><\/a>.<\/div>\n
18) Chabner BA, Palmer AC<\/strong> (2018)
\nClinical Strategies for Cancer Treatment: The Role of Drugs<\/a>, in
\nCancer Chemotherapy, Immunotherapy and Biotherapy<\/em><\/strong>, 6th Ed., Wolters Kluwer Health.<\/div>\n
17) Weinstein ZB, Kuru N, Kiriakov S, Palmer AC<\/strong>, Khalil AS, Clemons PA, Zaman MH, Roth FP, Cokol M. (2018)
\nModeling the impact of drug interactions on therapeutic selectivity.<\/a>
\nNature Communications<\/em><\/strong> 9:p3452<\/div>\n
16) Palmer AC<\/strong>, Chait R, Kishony R (2018)
\nNon-optimal gene expression creates latent potential for antibiotic resistance.<\/a>
\nMolecular Biology and Evolution<\/em><\/strong> 35:p2669<\/div>\n
15) Palmer AC<\/strong>, Sorger PK (2017)
\nCombination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy.<\/a>
\nCell<\/em><\/strong> 171:p1678
\nNews in Cell<\/em><\/a>, Nature<\/em><\/a>, Harvard Medical School<\/em><\/a>, The Medicine Maker<\/em><\/a>, BioCentury<\/em><\/a>, ecancer<\/em><\/a>, MedicalXpress<\/em><\/a>, Practical Oncology<\/em><\/a>.<\/div>\n
14) Schultz D, Palmer AC<\/strong>, Kishony R. (2017)
\nRegulatory dynamics determine cell fate following abrupt antibiotic exposure.<\/a>
\nCell Systems<\/em><\/strong> 5:p509<\/div>\n
13) Hao N, Palmer AC<\/strong>, Dodd IB, Shearwin KE (2017)
\nDirecting traffic on DNA \u2013 How transcription factors relieve or induce transcriptional interference.<\/a>
\nTranscription<\/em><\/strong> 8:p120<\/div>\n
12) Palmer AC<\/strong> (2016)
\nThe many genes of drug mechanism.<\/a> (News)
\nNature Chemical Biology<\/em><\/strong> 12:p57<\/div>\n
11) Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC<\/strong>, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ (2016)
\nOvercoming Therapeutic Resistance in HER2-Positive Breast Cancers With CDK4\/6 Inhibitors.<\/a>
\nCancer Cell<\/em><\/strong> 29:p255
\nNews in Cancer Discovery<\/em><\/a>, Cancer Cell<\/em><\/a>.<\/div>\n
10) Chait R, Palmer AC<\/strong>, Yelin I, Kishony R (2016)
\nPervasive selection for and against antibiotic resistance in inhomogeneous multi stress environments<\/a>.
\nNature Communications<\/em><\/strong> 7:p10333<\/div>\n
9) Hao N, Palmer AC<\/strong>, Ahlgren-Berg A, Shearwin KE, Dodd IB (2016)
\nThe role of repressor kinetics in relief of transcriptional interference between convergent promoters.<\/a>
\nNucleic Acids Research<\/em><\/strong> 44:p6625<\/div>\n
8) Palmer AC<\/strong>*, Toprak E*, Baym M, Kim S, Veres A, Bershtein S, Kishony R (2015) (*equal)
\nDelayed commitment to evolutionary fate in antibiotic resistance fitness landscapes.<\/a>
\nNature Communications<\/em><\/strong> 6:p7385<\/div>\n
7) Palmer AC<\/strong> and Kishony R (2014)
\nOpposing effects of target overexpression reveal drug mechanisms.<\/a>
\nNature Communications<\/em><\/strong> 5:p4296<\/div>\n
6) Palmer AC<\/strong> and Kishony R (2013)
\nUnderstanding, predicting and manipulating the genotypic evolution of antibiotic resistance.<\/a>
\nNature Reviews Genetics<\/em><\/strong> 14:p243<\/div>\n
5) Palmer AC<\/strong>, Egan JB, Shearwin KE (2011)
\nTranscriptional interference by RNA polymerase pausing and dislodgement of transcription factors.<\/a>
\nTranscription<\/em><\/strong> 2:p9<\/div>\n
4) Palmer AC<\/strong>, Angelino E, Kishony R (2010)
\nChemical decay of an antibiotic inverts selection for resistance.<\/a>
\nNature Chemical Biology<\/em><\/strong> 6:p105
\nNews in Nature Chemical Biology<\/em><\/a> and Chemistry World<\/em><\/a>.<\/div>\n
3) Palmer AC<\/strong>, Ahlgren-Berg A, Egan JB, Dodd IB, Shearwin KE (2009)
\nPotent transcriptional interference by pausing of RNA polymerases over a downstream promoter.<\/a>
\nMolecular Cell<\/em><\/strong> 34:p545<\/div>\n
2) Palmer AC<\/strong> and Shearwin KE (2009)
\nGuidance for data collection and computational modelling of regulatory networks.<\/a>
\nMethods in Molecular Biology<\/em><\/strong> 541:p337<\/div>\n
1) Sneppen K, Dodd IB, Shearwin KE, Palmer AC<\/strong>, Schubert RA, Callen BP, Egan JB. (2005)
\nA mathematical model for transcriptional interference by RNA polymerase traffic in Escherichia coli.<\/a>
\nJournal of Molecular Biology<\/em><\/strong> 18:p399<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Google Scholar NCBI Bibliography 43) Pomeroy AE, Sworder BJ, Plana D, Cao Y, Alizadeh AA, Palmer AC (2026) A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma Blood Cancer Discovery 7:p41 News in\u00a0Blood Cancer Discovery 42) Pantazis JC, Palmer AC (2025) Cross-resistance of Belinostat and Romidepsin in Non\u2013T Follicular … Read more<\/a><\/p>\n","protected":false},"author":22429,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2269","page","type-page","status-publish","hentry","odd"],"acf":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/wp-json\/wp\/v2\/pages\/2269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/wp-json\/wp\/v2\/users\/22429"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/wp-json\/wp\/v2\/comments?post=2269"}],"version-history":[{"count":13,"href":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/wp-json\/wp\/v2\/pages\/2269\/revisions"}],"predecessor-version":[{"id":2424,"href":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/wp-json\/wp\/v2\/pages\/2269\/revisions\/2424"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/pharm\/palmerlab\/wp-json\/wp\/v2\/media?parent=2269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}